Chapter 14 — Key Takeaways
Three market failures in healthcare
-
Information asymmetry: patients don't know what they need (the doctor diagnoses AND sells the treatment), can't evaluate quality, and face opaque prices. The principal-agent problem is severe.
-
Moral hazard: insurance reduces the patient's out-of-pocket cost, which encourages overuse. The RAND experiment confirmed that lower cost-sharing → more utilization. Balancing access and overuse is the central design problem.
-
Adverse selection: if insurance is optional, healthy people opt out, sicker people stay, premiums rise, more healthy people leave — the "death spiral." The ACA's individual mandate was designed to prevent this.
The three failures interact: information asymmetry prevents patients from controlling moral hazard; moral hazard drives up costs, worsening adverse selection; adverse selection thins pools, reducing coverage and exacerbating the information problem.
The U.S. healthcare paradox
The U.S. spends ~$13,500 per person per year on healthcare (~17% of GDP) — roughly double the rich-country average. Outcomes are worse on most metrics: lower life expectancy (~77 vs. ~82 in peer countries), higher infant mortality, higher preventable death rates.
Three reasons it costs more: 1. Higher prices, not more services — "it's the prices, stupid" (Gerard Anderson) 2. Administrative complexity — 15–30% of spending is administrative waste 3. Fragmented coverage — 26 million uninsured use expensive settings and present late
Three reasons it's hard to change: 1. Concentrated interests (hospitals, pharma, insurers, specialists lobby to protect revenue) 2. Employer-sponsored insurance creates lock-in (losing job = losing insurance) 3. Ideological polarization (Medicare for All vs. market-based reform vs. status quo)
Four healthcare systems compared
| System | Payer | Strengths | Weaknesses |
|---|---|---|---|
| US mixed | Multiple (private, Medicare, Medicaid, ACA, VA) | Innovation, specialist quality, choice | Highest cost, worst outcomes among rich countries, 26M uninsured |
| UK NHS | Government (single-payer, government-run) | Universal, low admin cost, free at point of use | Wait times, chronic underfunding, limited choice |
| Canada | Government payer, private delivery | Universal, simple admin, no bills | Wait times, limited drug/dental/vision coverage |
| Singapore | Mandatory savings + catastrophic insurance + safety net | Lowest cost among these, good outcomes, cost control | Out-of-pocket burden on poor; small/wealthy/young population |
No system is "the" answer. Each makes different tradeoffs among cost, access, quality, and choice.
The COVID lens
Strengths exposed: rapid vaccine development, treatment innovation, intensive care capacity. Weaknesses exposed: uneven access, essential-worker vulnerability, fragmented public health response, ruinous hospital bills.
What the chapter does NOT settle
The U.S. system is uniquely expensive and uniquely poor-performing. The diagnosis is structural (prices, admin waste, fragmented coverage). The fix requires some combination of cost control, coverage expansion, and administrative simplification. The specific combination depends on values. The political constraints are the binding obstacle.
Themes this chapter touched
- Markets power+imperfect — healthcare is the most dramatic market failure most readers experience
- Tradeoffs — every system trades off cost, access, quality, and choice differently
- Disagreement — about which system is best and which reforms are politically feasible
- Behavioral — moral hazard is partly behavioral; patients respond to prices and defaults
- Affects daily life — healthcare bills, insurance, access, COVID
One sentence summary
Healthcare markets fail because of information asymmetry, moral hazard, and adverse selection — and no country's system has fully solved these problems, which is why healthcare is simultaneously the most important and the most contested policy domain in the rich world.